Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
Crossref DOI link: https://doi.org/10.1186/s12959-015-0051-3
Published Online: 2015-06-11
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bamber, Luke
Muston, Dominic
McLeod, Euan
Guillermin, Anne
Lowin, Julia
Patel, Raj
License valid from 2015-06-11